Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

74 results about "Anti metastasis" patented technology

Enzyme-activated anti-tumor prodrug compounds

Disclosed are enzyme-activated anti-tumor and anti-metastatic prodrug compounds. The specific enzymes are collagenase(IV) and elastase. Also disclosed are methods of making and using such compounds.
Owner:BOEHRINGER INGELHEIM PHARMA INC

Inhibition of AXL Signaling in Anti-Metastatic Therapy

Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potentatial of a cancer thereof

The present invention relates to novel methods and compositions for detection and isolation of cancer cells with metastatic potential. The invention further relates to assays for measuring the metastatic potential of such cancer cells and drug screening assays for the identification of agents having anti-metastatic potential. The present invention further provides methods and compositions for inhibiting the metastatic potential of cancer cells by modulating the activity of serine integral membrane proteases [(SIMP) consisting of seprase and dipedidyl peptidase IV (DPPIV)]expressed on the surface of metastasizing cancer cells.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK

Cancer Metastasis Inhibitor

The present inventors used a model of intrasplenically induced liver metastasis to determine whether or not NF-κB activation in the liver is involved in the onset of metastatic tumors. When IKKβ was deleted from both liver cells and hematopoietically-derived cells, the onset of tumors was reduced remarkably. Tumor cells activated neighboring bone marrow cells (Kupffer cells) and produced mitogens such as interleukin (IL)-6, and this promoted angiogenesis and growth of tumors. The mitogen production depended on NF-κB in hematopoietically-derived Kupffer cells. Furthermore, treatment with an anti-IL-6 receptor antibody decreased the degree of metastatic tumor development. That is, the present inventors showed that tumor metastasis depends on inflammation, and proinflammatory intervention that targets Kupffer cells is useful for chemical prevention of metastatic tumors. Furthermore, it was shown that inhibition of the IKKβ / NF-κB signal transduction pathway, in particular IL-6 inhibition, can be utilized for anti-metastasis agents.
Owner:MAEDA CORPORATION

Antibodies to il-6 and use thereof

The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others. Additional preferred embodiments of the subject invention relate to therapeutic compositions and methods treating or preventing rheumatoid arthritis, especially subcutaneous and intravenous formulations and dosage regimens using IL-6 antagonists according to the invention, as well as methods for preventing or treating GVHD or leukemia relapse in subjects receiving transplanted cells, tissue or organs, use thereof in the treatment or prevention of mucositis, and use thereof to potentiate the cytotoxic, apoptotic, and anti-metastatic or anti-invasive effects of chemotherapeutics and radiation on cancers, especially cancers that have developed a resistance to radiation or chemotherapy, such as an EGFR inhibitor.
Owner:VITAERIS INC +1

Methods and uses thereof of prosaposin

InactiveUS20100144603A1Extended half-lifeFacilitating recombinant protein expressionAntibacterial agentsBiocideAbnormal tissue growthLymphatic Spread
The invention relates to methods for treating of tumor metastasis, methods for preventing, inhibiting, and predicting tumor recurrence and tumor metastasis, and methods of preventing cancer development for one at risk of developing cancer, for one diagnosed with a benign cancer, and / or for one diagnosed with malignant cancer. The invention also relates to methods of treating angiogenesis-dependent diseases and disorders. In addition, the invention provides: (1) a method for screening for tumor / cancer derived angiogenesis and metastasis factors; (2) a method for screening for compounds that inhibit angiogenesis and metastasis; (3) a method for screening for compounds that promote anti-angiogenesis and anti-metastasis activities; (4) a method for cancer prognosis evaluation; (5) a method for predicting the tissue specificity of a metastatic cancer; (6) a method for determining likelihood of metastasis; and (7) a method for cancer prognosis evaluation by the surveillance of metastasis development.
Owner:CHILDRENS MEDICAL CENT CORP

Nanogene therapy for cell proliferation disorders

The present invention concerns particles comprising a chitin component, such as chitosan or a derivative thereof, associated with a polynucleotide encoding an interferon (IFN) molecule, 2-5′ oligoadenylate synthetase (2-5 AS), or a combination thereof. Preferably, the chitin component comprises chitosan or a derivative thereof. The particles of the invention are useful for delivery and expression of the interferon-encoding and / or 2-5 AS-encoding polynucleotide within a host in vitro or in vivo. The invention further concerns pharmaceutical compositions comprising particles of the invention and a pharmaceutically acceptable carrier, and a method for producing particles of the present invention. The present invention further pertains to a method of inducing apoptosis in a cancer cell, such as a lung cancer cell, by contacting a target cancer cell in vitro or in vivo with an effective amount of particles of the invention. In one embodiment, a therapeutically effective amount of particles are administered to target cancer cells within a patient in vivo, for treatment of cancer, such as lung cancer. The particles and therapeutic methods of the invention provide anti-metastatic and anti-cancer therapeutics for cancer patients, particularly lung cancer patients.
Owner:UNIV OF SOUTH FLORIDA

Anticancer compounds and methods

The testing of tumor cells, including human tumors capable of metastases, in assays employing fibronectin-depleted substrates is described. Ex vivo induction of cells, including biopsied human cells, is performed with invasion-inducing agents. Additionally, anti-cancer chemotherapeutics are described. Specifically, chemotherapeutic agents which have anti-metastatic and anti-growth properties are described including non-peptide compositions of matter.
Owner:RGT UNIV OF MICHIGAN

Grp94 inhibitors

The present disclosure provides a series of compounds which exhibit isoform selective inhibition of GRP94, a homologue of Hsp90 that is localized to the endoplasmic recticulum. Through GRP94 inhibition, these compounds are likely to manifest anti-cancer, anti-inflammatory, anti-metastasis, and immunosuppressive activities, as well as utility in the treatment of neurodegenerative diseases, and diabetes.
Owner:UNIVERSITY OF KANSAS

Medicinal application of 15-benzyl subunit-1 4-deoxy-11,12-dehydrogenation andrographolide derivative

The invention belongs to the technical field of medicine, discloses the application of andrographolide derivative in preparation antineoplastic agents, and relates to 15-benzyl subunit -14-deoxy-11,12-dehydrogenation andrographolide derivative and 3,19 esters thereof. The experience shows that the chemical compounds have the remarkable effects of restraining cancer cell cloning and forming and resisting migration of cancer cell and human vascular endothelial; and the chemical compounds show stronger effects of restraining tumor growth, antimetastasis and antiangiogenic in a mice transplanting tumour animal model. The chemical compounds are used as activity components for preparing antineoplastic agents, have the advantages of high efficient and low toxicity. the invention provides a new drug way for curing and preventing transfer of the tumour, expands selection range of clinical pharmacy, and is significant to taking full advantage of plant resources of the common andrographis herb.
Owner:ZHENGZHOU UNIV

Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng

Provided is a composition that contains, as an active ingredient, an extract or polysaccharides separated from the leaves and / or stems of plants belonging to Panax genus, for an anticancer drug or its adjuvant, having an effect on the activity of hemotopoiesis enhancement, cancer metastasis inhibition, bone marrow defense, etc . . . , and a process for preparation of the extract from the leaves and / or stems of plants belonging to Panax genus.
Owner:YUNGJIN PHARM CO LTD

Modified AXL Peptides and Their Use in Inhibition of AXL Signaling in Anti-Metastatic Therapy

ActiveUS20150315553A1Determining likelihoodDetermining susceptibilityHybrid immunoglobulinsAntibody mimetics/scaffoldsGAS6Protein activity
Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV +1

Method for screening medicament taking focal adhesion kinase (FAK) transcriptional regulation as target spot and application

The invention belongs to the field of biotechnology, and in particular relates to a method for screening a medicament taking focal adhesion kinase (FAK) transcriptional regulation as a target spot. The method mainly comprises the steps of: expressing a reporter gene in a tumour cell by an expression vector which contains an FAK promoter and the reporter gene driven by a core segment; and detecting an expression level of the reporter gene by using a cell model, and evaluating the regulation of the medicament for the FAK promoter and the influence on a cell function which is medicated by the FAK. By using the method, the medicament taking the FAK transcriptional regulation as the target spot can be screened, and a compound obtained by screening has the application prospect for preparing an anti-metastasis medicament.
Owner:JIANGSU TARGET BIOMEDICINE RES INST

Traditional Chinese medicine composition capable of inhibiting tumor metastasis and preparation method and application thereof

InactiveCN109908302AInhibit transferInhibition of Migratory InvasionAntineoplastic agentsPlant ingredientsLife qualityMda mb 231
The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition capable of inhibiting tumor metastasis. Active ingredients of the traditional Chinese medicine composition include, by weight, 20-50 parts of radix astragali, 10-20 parts of rhizoma curcumae, 20-40 parts of radix pseudostellariae, 10-20 parts of poriacocos, 20-40 parts of rhizoma atractylodis macrocephalae, 20-40 parts of coix seed, 10-20 parts of fructus ligustri lucidi, 10-20 parts of fructus lycii, 10-20 parts of herba cistanche, 10-20 parts of fructus corni, 10-20 parts of radix polygonum multiflorum preparata, 15-30 parts of hedyotis diffusa and 15-30 parts of herba scutellariae barbatae. The invention further provides a preparation method and application of the traditional Chinese medicine composition. Main treatment rules of the composition are to tonify spleen and kidney, the composition can remarkably inhibit breast cancer cell MDA-MB-231 scratch formation, can inhibit cell migration and intrusion and has remarkable anti-metastasis effect; cytological experiments prove that the composition has efficacy of inhibiting tumor metastasis, and clinical experiments prove that the composition has remarkable effect on improving life quality of tumor patients.
Owner:GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE

Use of entrained neutrophils to treat metastatic and micrometastatic disease in at risk patients

The present invention relates generally to compositions and methods for treating cancer patients with a poor prognosis, and to therapeutic modalities for improving prognosis by combating metastasis and abrogating chemoresistance in cancer cells. In particular, the invention relates to the role of white blood cells, i.e. neutrophils and neutrophil-like cells, in preventing the spread of cancer from a primary tumor to secondary locations in the body. The invention provides methods for reducing or delaying the spread of metastatic cancer cells in a patient at risk for metastatic tumor development, at risk for metastatic relapse, i.e. prophylactic methods, and treating patients suffering from metastatic tumors.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

In vivo quantitative screening test for Anti-metastasis treatment efficacy

The present invention is directed to methods for evaluating the efficacy of a cancer treatment for (i) inhibiting metastasis in a subject, (ii) inhibiting local cancer cell movement, and (iii) inhibiting cancer cell proliferation. The present invention is further directed to methods for monitoring cell motility in a subject. The present invention is also directed to kits for performing any of the above methods.
Owner:NAT INST OF HEALTH REPRESENTED BY THE SEC OF THE DEPT OF HEALTH & HUMAN SERVICES NAT INST OF HEALTH

Method for screening anti-tumor metastasis compounds

The invention provides a method for screening anti-tumor metastasis compounds. By means of the change of the expression level of an EMT marker in tumor cells, a stable and effective system for screening the anti-tumor metastasis compounds is established, screening of a large quantity of compounds can be achieved, anti-metastasis new drug precursors can be found within a short period, and a technical solution is provided for developing a series of anti-cancer new drugs.
Owner:EXPLORING HEALTH LLC

Active fraction having anti-cancer and anti-metastic activity isolated from leaves and stems of ginseng

This invention Provides a composition that contains, as an active ingredient, an extract or polysaccharides separated from plants belonging to Acanthopanax genus, for an anticancer drug, or its adjuvant having an effect on the enhancement of hemotopoiesis, defense of bone marrow, inhibition of radiation side effects, etc., and a method of preparing the extract from the Acanthopanax genus plants.
Owner:MERENS CO LTD

Ruthenium complex as well as preparation method and application thereof

The invention discloses a ruthenium complex containing a pyridine derivative as well as a preparation method and an application of the ruthenium complex. The structural formula of the complex is shown in the formula (I). The preparation method comprises the steps: grinding a reaction initiator trans-[RuCl4(SOR1R2)2][(SOR1R2)2H] into fine powder; stirring the initiator and ligand or performing ultrasonic oscillation in a reaction solvent, wherein the molar rate of the initiator to the ligand is 1:2-1:8 and the reaction temperature is 25-80 DEG C; or carrying out backflow; filtering precipitate formed after ultrasonic oscillation, and washing with acetone and diethyl ether; and drying by a silicon rubber dryer and keeping overnight. According to the preparation method of the ruthenium complex, the reaction time is short and the yield is high; and by using the prepared NA MI-A derivate, the anti-metastasis pesticide effect of Lewis experimental lung-cancer mice is significant, and the toxicity is low.
Owner:MACAU UNIV OF SCI & TECH

PNC detection kit for detecting tumor invasion and application thereof

The invention relates to the field of biotechnology, especially to a detection kit of a novel target PNC for detection of tumor invasion and application thereof. The first detection antibody of the PNC detection kit for detecting tumor invasion is a PTB or CUG-BP1 antibody. The invention describes composition and application methods of a PNC immunohistochemical detection kit and a PNC immunofluorescence detection kit used for detecting tumor invasion. Furthermore, the invention also provides a method for screening a novel anti-metastasis compound and a Chinese herbal medicine monomer thereof; and the method for screening the novel anti-metastasis compound is also applicable to screening of small molecule compounds and Chinese herbal medicine monomers thereof. According to the invention, the proportion of PNC in a tissue sample of a cancer patient obtained through paracentesis is detected by using the PNC kits, so detection is simple and convenient, is easy to operate and has good stability; the proportion of PNC in tumor cells which have been affected by the compound is detected by using the PNC kits, computer programming and analysis are cooperatively used, so high throughput screening of a novel drug is realized.
Owner:ZHEJIANG UNIV

XL-2 human lung cancer highly metastatic cell line and applications

The invention belongs to the field of cytobiology, and discloses a human lung cancer XL-2 highly metastatic cell line, called XL-2sci for short. The human lung cancer XL-2 highly metastatic cell line is characterized by being prepared through the step that conventional lung cancer cells XL-2 cells are subjected to animal in-vivo cyclic screening, and the conventional lung cancer cells XL-2 cells are preserved in the China Center for Type Culture Collection (CCTCC), and have the preservation number CCTCC NO C201282. The human lung cancer XL-2 highly metastatic cell line has the advantages that (1) through the repeated in-vivo screening, a human lung cancer XL-2 highly metastatic cell line model and a human lung cancer XL-2 highly metastatic cell line are successfully established, the metastasis rate is high, the metastasis is stable, the intuition is good, and the targeting is strong; (2) with the human lung cancer XL-2 highly metastatic cell line provided by the invention, an ideal model is provided for the prevention and cure research and anti-metastasis treatment on lung cancer.
Owner:SHANGHAI INST OF ONCOLOGY

Cholesterol-low molecular weight heparin nano preparation for anti-tumor and anti-metastasis therapy and preparation method thereof

The invention relates to a cholesterol-low molecular weight heparin nano preparation loaded with anti-tumor drugs for anti-tumor and anti-metastasis therapy and a preparation method thereof. Specifically, the nano preparation is characterized in that cholesterol with excellent biocompatibility serves as a hydrophobic fragment and a hydrophobic drug reservoir for encapsulation of an anti-tumor drug, hydrophilic low molecular weight heparin with anti-metastasis activity serves as a shell so as to prepare the novel nano preparation for preventing postoperative recurrence, and therefore tumor cells can be killed, and meanwhile, the effect of inhibiting tumor cell metastasis can be achieved. The nano preparation has the advantages that the drug loading capacity is within 5-20wt%, the prepared nano preparation has an injectable property, administration is realized through tail intravenous injection, and therefore the anti-tumor effect of the drug can be improved, and meanwhile, the anti-metastasis activity of the low molecular weight heparin can be exerted.
Owner:CHINA PHARM UNIV

Human lung adenocarcinoma cell LC-21 and application thereof

The invention discloses a human lung adenocarcinoma cell LC-21, which belongs to the field of cytobiology. The human lung adenocarcinoma cell is characterized by being preserved in China Center for Type Culture Collection with an accession number of CCTCC No. C201287. The invention has the following advantages: (1) through repeated in-vitro screening, a human lung adenocarcinoma cell LC-21 cell line model and a human lung adenocarcinoma cell LC-21 cell line are successfully established, and the established model and cell line have a high metastasis rate, stable metastasis, good visualizability and strong targeting performance; and (2) the human lung adenocarcinoma cell LC-21 cell line provides an ideal model for prevention and cure research and anti-metastasis treatment of lung cancers.
Owner:SHANGHAI INST OF ONCOLOGY

EMS1/cortactin-targeted multitarget siRNA molecule, and applications thereof

The invention belongs to the technical field of siRNA molecule of targeting tumour-related gene, and relates to an EMS1 / cortactin-targeted multitarget siRNA molecule, and applications thereof. The EMS1 / cortactin-targeted multitarget siRNA molecule comprises following sequences: EMS1 / cortactin siRNA-5 sense strand and antisense strand, EMS1 / cortactin siRNA-6 sense strand and antisense strand, and EMS1 / cortactin siRNA-7 sense strand and antisense strand. Expression of EMS1 / cortactin is inhibited via transfection of human liver cancer (HCC)SMMC-7721 cell line, gene level is about 80%, down-regulating level is relatively stable and accurate. The multitarget siRNA is adopted in HCC gene chip detection, research of EMS1 / cortactin expression on HCC transferring regulating molecular mechanism, and preparation of EMS1 / cortactin-targeted anti-metastasis nucleic acid drugs.
Owner:NANTONG UNIV XINGLIN COLLEGE +2

Preparation and application of nano medicine targeting at adhesion factor ICAM-1

The invention belongs to the field of preparation of anti-tumor metastasis medicines, and specifically relates to a chitosan nano medicine targeting at adhesion factor ICAM-1 and preparation and application thereof. Ursolic acid and chitosan are coupled to obtain a CS-UA conjugate, an ICAM-1-CS-UA conjugate is formed from the CS-UA conjugate and ICAM-1 through an amido bond, and finally an ICAM-1-CS-UA nano medicine is formed by ionic crosslinking method. The nano medicine has many advantages such as high specificity, low toxic and side effects and simple operation, and provides a good application prospect for the development of anti tumor and anti metastatic drugs in clinic.
Owner:FUZHOU UNIVERSITY

ICAM-1 (Intercellular Adhesion Molecule 1) gene knockout tumor cell strain and application thereof

The invention relates to related study fields of cytobiology, molecular biology and the like and discloses an ICAM-1 (Intercellular Adhesion Molecule 1) gene knockout tumor cell strain and applicationthereof. The invention discloses sgRNA (Small Guide Ribonucleic Acid) which targets to a PAM (Protospacer Adjacent Motif) site of an ICAM-1 gene of a human genome; through transfection recombinant CRISPR plasmid transfection, the ICAM-1 gene of a HelA cell can be efficiently knocked out; through resistance screening with puromycin, a conventional limiting dilution method is not used in the screening process, but a relatively convenient and concise monoclonal picking method is used instead, and thus the experiment cycle is greatly shortened. With the ICAM-1 knockout cell strain, a novel research platform is established for studying adhesion and metastasis process of tumor cells, experiments show that the adhesion property of HeLa is remarkably degraded after ICAM-1 is knocked out, molecular mechanisms of mutual actions of ICAM-1 with different cell factors can be studied, and meanwhile treatment mechanisms and molecular targets related to anti-metastasis medicines can be well studied.
Owner:FUZHOU UNIV

Chinese adenocarcinoma of lung cell strain without transferring potential

The invention relates to a Chinese adenocarcinoma of lung cell strain Yang6 without transferring potential and an application and belongs to the biological zooblast system field. The Chinese adenocarcinoma of lung cell strain without transferring potential adopts pleural effusion of initial diagnosis later period adenocarcinoma of lung patients as cell primary culture, so that the Chinese adenocarcinoma of lung cell strain Yang6 without transferring potential is acquired, wherein a preservation number is CGMCC number (No.) 5404. The Chinese adenocarcinoma of lung cell strain Yang6 without transferring potential adherently grows on walls, possesses non-transitivity, and can be used as a people adenocarcinoma of lung comparative study cell model, wherein the shapes of cells are attractive and in a circle shape or a partial polygon shape, so that growth speed is low. The Chinese adenocarcinoma of lung cell strain without transferring potential has unique molecular biology character, heterogeneity, and polymorphism, and has a wide prospect in the application of disclosing a transferring mechanism of people adenocarcinoma of lung and selection of anti-metastasis drugs.
Owner:SHANGHAI CHEST HOSPITAL

Anticancer and antiprotozoal dihydroartemisinene and dihydroartemisitene dimers with desirable chemical functionalities

This invention comprises compositions containing dihydroartemisinin- and dihydroartemisitene-dimers with activity as anticancer or anticancer metastasis agents and anti-protozal, including anti-malarial and anti-leishmanial properties. This invention also describes methods of preparation of these compositions and methods of use of such compositions for the treatment of cancer or prevention of cancer metastasis, and protozoal infections, including malaria, or leishmaniasis. The compounds of this invention represent a potential new class of anti-tumor or anti-metastasis agents, one that has shown promising activity against solid tumors.
Owner:ELSOHLY LAB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products